Literature DB >> 28106064

Precision medicine for disease modification in Parkinson disease.

Alberto J Espay1, Patrik Brundin2, Anthony E Lang3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28106064     DOI： 10.1038/nrneurol.2016.196

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  62 in total

Review 1.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

Review 2.  Pathogenic mechanisms of neurodegeneration in Parkinson disease.

Authors:  Stephen Mullin; Anthony H V Schapira
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 4.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

5.  Role of creatine as biomarker of mitochondrial diseases.

Authors:  Sonia Pajares; Angela Arias; Judit García-Villoria; Paz Briones; Antonia Ribes
Journal:  Mol Genet Metab       Date:  2012-12-03       Impact factor: 4.797

6.  Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.

Authors:  C W Shults
Journal:  Acta Neurol Scand Suppl       Date:  1993

7.  Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease.

Authors:  Vincenzo Donadio; Alex Incensi; Cristina Piccinini; Pietro Cortelli; Maria Pia Giannoccaro; Agostino Baruzzi; Rocco Liguori
Journal:  Ann Neurol       Date:  2015-12-29       Impact factor: 10.422

Review 8.  Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker.

Authors:  Naomi P Visanji; Connie Marras; Lili-Naz Hazrati; Louis W C Liu; Anthony E Lang
Journal:  Mov Disord       Date:  2013-12-26       Impact factor: 10.338

9.  Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients.

Authors:  Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

Review 10.  Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.

Authors:  Sonia George; Patrik Brundin
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568
View more
  39 in total

Review 1.  Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?

Authors:  Alessio Di Fonzo; Edoardo Monfrini; Roberto Erro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

Review 3.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

4.  LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.

Authors:  Katharina A Schindlbeck; An Vo; Nha Nguyen; Chris C Tang; Martin Niethammer; Vijay Dhawan; Vicky Brandt; Rachel Saunders-Pullman; Susan B Bressman; David Eidelberg
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

Review 5.  Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.

Authors:  Marco Onofrj; Alberto J Espay; Laura Bonanni; Stefano Delli Pizzi; Stefano L Sensi
Journal:  Mov Disord       Date:  2019-07-15       Impact factor: 10.338

Review 6.  Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Authors:  Alberto J Espay; Michael A Schwarzschild; Caroline M Tanner; Hubert H Fernandez; David K Simon; James B Leverenz; Aristide Merola; Alice Chen-Plotkin; Patrik Brundin; Marcelo A Kauffman; Roberto Erro; Karl Kieburtz; Daniel Woo; Eric A Macklin; David G Standaert; Anthony E Lang
Journal:  Mov Disord       Date:  2017-02-24       Impact factor: 10.338

Review 7.  Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Authors:  Michaela E Johnson; Benjamin Stecher; Viviane Labrie; Lena Brundin; Patrik Brundin
Journal:  Trends Neurosci       Date:  2018-10-17       Impact factor: 13.837

8.  [Application of intracranial lead reconstruction in deep brain stimulation therapy in patients with Parkinson's disease].

Authors:  Xiaobin Zheng; Lianghong Yu; Xinlong Wan; Huiqing Wang; Ting Yu; Qiu He; Zhangya Lin; Dezhi Kang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

Review 9.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

Review 10.  Virtual reality in research and rehabilitation of gait and balance in Parkinson disease.

Authors:  Colleen G Canning; Natalie E Allen; Evelien Nackaerts; Serene S Paul; Alice Nieuwboer; Moran Gilat
Journal:  Nat Rev Neurol       Date:  2020-06-26       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.